Ethyl 6-cyclobutyloxy-2-(1-methyl-2-oxabicyclo[2.2.1]heptan-4-yl)pyrazolo[3,4-b]pyridine-5-carboxylate
C20H25N3O4 — CID 170692861
Data last refreshed: (MolForge compound catalog, from PubChem)
About Ethyl 6-cyclobutyloxy-2-(1-methyl-2-oxabicyclo[2.2.1]heptan-4-yl)pyrazolo[3,4-b]pyridine-5-carboxylate
Ethyl 6-cyclobutyloxy-2-(1-methyl-2-oxabicyclo[2.2.1]heptan-4-yl)pyrazolo[3,4-b]pyridine-5-carboxylate (PubChem CID 170692861) has the molecular formula C20H25N3O4 and a molecular weight of 371.44 g/mol. Its IUPAC name is ethyl 6-cyclobutyloxy-2-(1-methyl-2-oxabicyclo[2.2.1]heptan-4-yl)pyrazolo[3,4-b]pyridine-5-carboxylate.
Molecular Properties
| Compound Name | Ethyl 6-cyclobutyloxy-2-(1-methyl-2-oxabicyclo[2.2.1]heptan-4-yl)pyrazolo[3,4-b]pyridine-5-carboxylate |
|---|---|
| PubChem CID | 170692861 |
| Molecular Formula | C20H25N3O4 |
| Molecular Weight | 371.44 g/mol |
| Exact Mass | 371.18 |
| IUPAC Name | ethyl 6-cyclobutyloxy-2-(1-methyl-2-oxabicyclo[2.2.1]heptan-4-yl)pyrazolo[3,4-b]pyridine-5-carboxylate |
| SMILES | CCOC(=O)c1cc2cn(C34CCC(C)(C3)OC4)nc2nc1OC1CCC1 |
| InChI | InChI=1S/C20H25N3O4/c1-3-25-18(24)15-9-13-10-23(20-8-7-19(2,11-20)26-12-20)22-16(13)21-17(15)27-14-5-4-6-14/h9-10,14H,3-8,11-12H2,1-2H3 |
| InChIKey | AVKNBDOULJPKQX-UHFFFAOYSA-N |
| XLogP | 3.21 |
| TPSA | 75.47 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 371.44 |
| LogP ≤ 5 | 3.21 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 170692861 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.